Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vitalhub Corp T.VHI

Alternate Symbol(s):  VHIBF

VitalHub Corp. is a software company. It offers software for health and human service providers designed to simplify the user experience and optimize outcomes. It offers a comprehensive suite of software-as-a-service solutions, which include electronic health record (EHR), case management, care coordination, and optimization; patient flow, operational visibility, and patient journey... see more

TSX:VHI - Post Discussion

Vitalhub Corp > Targets Raised
View:
Post by retiredcf on Feb 06, 2024 9:29am

Targets Raised

Following recent marketing meetings, Eight Capital analyst Christian Sgro raised his target for shares of Vitalhub Corp.  to a new high on the Street, expecting the Toronto-based healthcare company to continue to grow through M&A activity.

“We see the recent leg-up in the share price as an overdue catch-up and believe 1) there is little risk to the stable fundamental outlook and 2) the valuation still remains attractive compared to peers,” he said.

On Monday, Vitalhub announced the $2.5-million acquisition of U.K.-based BookWise Solutions Ltd., which provides specialist scheduling software for healthcare and corporate organizations

“We like the BookWise acquisition, which we would frame as bite-sized and exactly in-line with management’s consolidation strategy. With ample balance sheet capacity, we think more accretive and synergistic M&A will likely come,” the analyst said.

“We are updating our model to include the acquisition of BookWise. We have maintained 25-per-cent adjusted EBITDA margins or higher given management’s recent commentary that these levels are sustainable. We calculate pro forma net cash of $27.3-million, and total available liquidity of $60-million.”

Mr. Sgro increased his target for Vitalhub shares to $6.25 from $5, keeping a “buy” recommendation. The average is $5.71.

“Vitalhub currently trades at 10.4 times 2025 estimated EV/adj. EBITDA,” he said. “We think the Canadian software equities ... serve as a strong reference for comparable valuation analysis, with small-to-mid cap peers trading at 14.1 times and large cap peers trading at 21.8 times. We think Vitalhub deserves a premium compared to peers, given the company’s defensive attributes, recurring software profile, and stable cash flow generation.”

Elsewhere, Canaccord Genuity’s Doug Taylor bumped his target to $5.50 from $5.25 with a “buy” rating.

“The deal closed immediately and brings a small but synergistic asset that complements the company’s roster of patient flow management solutions in the UK market and expands its Australian presence,” he said. “We note BookWise marks VitalHub’s first acquisition in a year as the company looks to re-accelerate its M&A activity in 2024, as we suggested in last week’s roadshow recap.”

Comment by Possibleidiot01 on Feb 11, 2024 8:52pm
Found a link for Eight Capital https://research.viiicapital.com/Reports/Research/2024/February/VHI020624.pdf
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities